We evaluated the effectiveness of one FDA approved EGFR inhibitor, gefitinib (848 nM), and one investigational EGFR inhibitor, poziotinib (172 nM), on the two NSCLC cell lines that carry EGFR mutations: H1650 (EGFR mutant exon 19 del(E746-A750)), and H1975 (EGFR mutant L858R and T790M) (Fig. 8). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.